2021
conference-abstract
OpenAlex
Justine J. Cunningham, Sundeep A. M. Chandra, Akinola Olumide Emmanuel, Allyse Mazzarelli et autres
Abstract Introduction: Ex vivo manufactured chimeric antigen receptor (CAR) T cell therapies are highly effective for treating B cell malignancies. However, the complexity, cost and time required to manufacture CAR T cells limits access. To overcome conventional ex vivo CAR T limitations, …
us
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Akinola Olumide Emmanuel, Patty Cruite, Hanane Ennajdaoui, Carmela Passaro et autres
Abstract CAR T cells are highly effective at inducing remissions in patients with refractory B cell malignancies. The ex vivo process used to manufacture these therapies limits patient access and exposes T cells to non-physiologic conditions in culture. Viral vectors are efficient …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Antoine J. Tanne, Sylvia Vincent, Benjamin Duckless, E Paltrinieri et autres
Abstract Immune checkpoint blockade (ICB) of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1) have shown durable responses in cancer patients. However, responses have been limited to a small subset of patients, and resistance to ICB therapy continues to …
us
(code pays fourni par la source)